Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 9:50 am EST.
The conference is set to take place from March 3-5, 2025. Interested parties can access the webcast through the 'Events' section of Arcutis' website, with the recording remaining available for 180 days after the conference.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni nell'immuno-dermatologia, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute TD Cowen. L'azienda parteciperà a una chiacchierata informale programmata per martedì 4 marzo 2025, alle 9:50 EST.
La conferenza si svolgerà dal 3 al 5 marzo 2025. Le parti interessate possono accedere al webcast tramite la sezione 'Eventi' del sito web di Arcutis, con la registrazione che rimarrà disponibile per 180 giorni dopo la conferenza.
Arcutis Biotherapeutics (Nasdaq: ARQT), una compañía biofarmacéutica en etapa comercial especializada en innovaciones en inmunodermatología, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud TD Cowen. La compañía participará en una charla informal programada para martes 4 de marzo de 2025, a las 9:50 am EST.
La conferencia se llevará a cabo del 3 al 5 de marzo de 2025. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos' del sitio web de Arcutis, con la grabación disponible durante 180 días después de la conferencia.
Arcutis Biotherapeutics (Nasdaq: ARQT), 면역 피부학 혁신을 전문으로 하는 상업 단계의 생물 제약 회사가 TD Cowen 제45회 연례 의료 회의에 참여할 예정이라고 발표했습니다. 회사는 2025년 3월 4일 화요일, 오전 9:50 EST에 예정된 화로 대화에 참여할 것입니다.
회의는 2025년 3월 3일부터 5일까지 진행됩니다. 관심 있는 분들은 Arcutis 웹사이트의 '이벤트' 섹션을 통해 웹캐스트에 접근할 수 있으며, 회의 후 180일 동안 녹화본을 이용할 수 있습니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé TD Cowen. L'entreprise participera à une discussion informelle prévue pour mardi 4 mars 2025, à 9h50 EST.
La conférence se déroulera du 3 au 5 mars 2025. Les parties intéressées peuvent accéder à la diffusion en direct via la section 'Événements' du site Web d'Arcutis, l'enregistrement restant disponible pendant 180 jours après la conférence.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der Handelsphase, das sich auf Innovationen in der Immunodermatologie spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 4. März 2025, um 9:50 Uhr EST geplant ist.
Die Konferenz findet vom 3. bis 5. März 2025 statt. Interessierte können über den Bereich 'Veranstaltungen' auf der Website von Arcutis auf den Webcast zugreifen, wobei die Aufzeichnung 180 Tage nach der Konferenz verfügbar bleibt.
- None.
- None.
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 45th Annual Health Care Conference, taking place March 3-5, 2025.
Details for the company’s participation are as follows:
Fireside Chat Date: Tuesday, March 4, 2025
Fireside Chat Time: 9:50 am EST
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release and the anticipated fireside chat discussion contain “forward-looking” statements, including, among others, statements regarding Arcutis’ potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
When is Arcutis (ARQT) presenting at the TD Cowen Healthcare Conference 2025?
How long will the ARQT TD Cowen Conference webcast be available for replay?
What type of presentation will ARQT give at the TD Cowen Healthcare Conference?
Where can investors access the ARQT TD Cowen Conference presentation?
What are the full dates for the TD Cowen Healthcare Conference where ARQT is presenting?
